Factors Influencing Pharmacokinetics of Tamoxifen in Breast Cancer Patients: A Systematic Review of Population Pharmacokinetic Models.
breast cancer
population pharmacokinetics
systematic review
tamoxifen
Journal
Biology
ISSN: 2079-7737
Titre abrégé: Biology (Basel)
Pays: Switzerland
ID NLM: 101587988
Informations de publication
Date de publication:
28 Dec 2022
28 Dec 2022
Historique:
received:
23
11
2022
revised:
21
12
2022
accepted:
25
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Tamoxifen is useful in managing breast cancer and it is reported to have significant variability in its pharmacokinetics. This review aimed to summarize reported population pharmacokinetics studies of tamoxifen and to identify the factors affecting the pharmacokinetics of tamoxifen in adult breast cancer patients. A systematic search was undertaken in Scopus, Web of Science, and PubMed for papers published in the English language from inception to 20 August 2022. Studies were included in the review if the population pharmacokinetic modeling was based on non-linear mixed-effects modeling with a parametric approach for tamoxifen in breast cancer patients. After initial selection, 671 records were taken for screening. A total of five studies were selected from Scopus, Web of Science, PubMed, and by manual searching. The majority of the studies were two-compartment models with first-order absorption and elimination to describe tamoxifen and its metabolites' disposition. The CYP2D6 phenotype and CYP3A4 genotype were the main covariates that affected the metabolism of tamoxifen and its metabolites. Other factors influencing the drug's pharmacokinetics included age, co-medication, BMI, medication adherence, CYP2B6, and CYP2C19 genotype. The disposition of tamoxifen and its metabolites varies primarily due to the CYP2D6 phenotype and CYP3A4 genotype. However, other factors, such as anthropometric characteristics and menopausal status, should also be addressed when accounting for this variability. All these studies should be externally evaluated to assess their applicability in different populations and to use model-informed dosing in the clinical setting.
Sections du résumé
BACKGROUND
BACKGROUND
Tamoxifen is useful in managing breast cancer and it is reported to have significant variability in its pharmacokinetics. This review aimed to summarize reported population pharmacokinetics studies of tamoxifen and to identify the factors affecting the pharmacokinetics of tamoxifen in adult breast cancer patients.
METHOD
METHODS
A systematic search was undertaken in Scopus, Web of Science, and PubMed for papers published in the English language from inception to 20 August 2022. Studies were included in the review if the population pharmacokinetic modeling was based on non-linear mixed-effects modeling with a parametric approach for tamoxifen in breast cancer patients.
RESULTS
RESULTS
After initial selection, 671 records were taken for screening. A total of five studies were selected from Scopus, Web of Science, PubMed, and by manual searching. The majority of the studies were two-compartment models with first-order absorption and elimination to describe tamoxifen and its metabolites' disposition. The CYP2D6 phenotype and CYP3A4 genotype were the main covariates that affected the metabolism of tamoxifen and its metabolites. Other factors influencing the drug's pharmacokinetics included age, co-medication, BMI, medication adherence, CYP2B6, and CYP2C19 genotype.
CONCLUSION
CONCLUSIONS
The disposition of tamoxifen and its metabolites varies primarily due to the CYP2D6 phenotype and CYP3A4 genotype. However, other factors, such as anthropometric characteristics and menopausal status, should also be addressed when accounting for this variability. All these studies should be externally evaluated to assess their applicability in different populations and to use model-informed dosing in the clinical setting.
Identifiants
pubmed: 36671744
pii: biology12010051
doi: 10.3390/biology12010051
pmc: PMC9855885
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : Indian Council of Medical Research
ID : 45/15/2022-PHA/BMS
Références
Clin Pharmacol Ther. 2011 May;89(5):718-25
pubmed: 21430657
Ann Oncol. 2008 Aug;19(8):1423-1429
pubmed: 18407954
Cancer Chemother Pharmacol. 2005 May;55(5):471-8
pubmed: 15685451
Clin Pharmacol Ther. 2021 May;109(5):1244-1255
pubmed: 33047329
CA Cancer J Clin. 2017 Nov;67(6):439-448
pubmed: 28972651
Lancet. 2001 Jul 28;358(9278):277-86
pubmed: 11498214
N Engl J Med. 2003 Feb 13;348(7):618-29
pubmed: 12584371
J Natl Cancer Inst. 2012 Mar 21;104(6):427-8
pubmed: 22395645
Clin Pharmacol Ther. 2020 Sep;108(3):661-670
pubmed: 32578187
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Clin Pharmacol Ther. 2010 Dec;88(6):814-7
pubmed: 20981001
Br J Clin Pharmacol. 2014 Sep;78(3):572-86
pubmed: 24697814
Drugs. 2001;61(12):1721-33
pubmed: 11693462
Breast Cancer Res Treat. 2005 Jun;91(3):249-58
pubmed: 15952058
Clin Pharmacol Ther. 2013 Aug;94(2):185-7
pubmed: 23872831
CPT Pharmacometrics Syst Pharmacol. 2013 Apr 17;2:e38
pubmed: 23887688
Pharmacogenomics. 2015;16(6):601-17
pubmed: 25893704
J Clin Oncol. 2007 Jul 20;25(21):3024-30
pubmed: 17536081
Transl Clin Pharmacol. 2019 Mar;27(1):19-23
pubmed: 32055577
Clin Pharmacol Ther. 2011 May;89(5):708-17
pubmed: 21451508
Expert Rev Clin Pharmacol. 2019 Jun;12(6):523-536
pubmed: 31008668
Adv Exp Med Biol. 2019;1152:51-64
pubmed: 31456179
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Clin Pharmacokinet. 2015 Jul;54(7):783-95
pubmed: 25637173
J Clin Oncol. 2011 Aug 20;29(24):3240-6
pubmed: 21768449
Front Pharmacol. 2020 Mar 31;11:283
pubmed: 32296331
Clin Pharmacol Ther. 1996 Apr;59(4):401-10
pubmed: 8612384
Clin Pharmacokinet. 2009;48(12):761-804
pubmed: 19902987
Expert Rev Clin Pharmacol. 2021 Jul;14(7):853-864
pubmed: 33851561
Asian Pac J Cancer Prev. 2013;14(4):2649-56
pubmed: 23725190
J Korean Med Sci. 2011 Aug;26(8):1007-13
pubmed: 21860550
J Clin Oncol. 2007 Sep 1;25(25):3837-45
pubmed: 17761971
J Natl Cancer Inst Monogr. 2004;(32):32-9
pubmed: 15263039
Breast Cancer Res. 2018 Dec 10;20(1):149
pubmed: 30526633
Br J Clin Pharmacol. 2022 Jul;88(7):3132-3152
pubmed: 35253251
Br J Cancer. 2010 Sep 7;103(6):765-71
pubmed: 20700120
Ther Drug Monit. 2015 Dec;37(6):733-44
pubmed: 25853922
Clin Pharmacokinet. 2015 Aug;54(8):797-810
pubmed: 25940823
Breast Cancer Res Treat. 2013 Sep;141(2):243-8
pubmed: 23996142
J Clin Oncol. 2007 Nov 20;25(33):5187-93
pubmed: 18024866
Front Pharmacol. 2017 Aug 24;8:582
pubmed: 28955222
Clin Pharmacol Ther. 2012 Oct;92(4):431-3
pubmed: 22910442
J Pharm Sci. 2007 Sep;96(9):2224-31
pubmed: 17518364
Clin Pharmacokinet. 2014 Feb;53(2):111-22
pubmed: 24327237
J Clin Oncol. 2017 Oct 20;35(30):3391-3400
pubmed: 28854070
Eur J Clin Pharmacol. 2022 Oct;78(10):1535-1553
pubmed: 35852584
J Natl Cancer Inst. 2002 Nov 6;94(21):1635-40
pubmed: 12419790
J BUON. 2016 Jan-Feb;21(1):27-34
pubmed: 27061527
Endocr Relat Cancer. 2004 Dec;11(4):643-58
pubmed: 15613444
Clin Pharmacokinet. 2009;48(11):689-723
pubmed: 19817501
BMC Pharmacol Toxicol. 2019 Dec 19;20(Suppl 1):81
pubmed: 31852530
Clin Pharmacol Ther. 2018 May;103(5):770-777
pubmed: 29385237